The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML.

Abstract

Overcoming drug resistance and targeting cancer stem cells remain challenges for curative cancer treatment. To investigate the role of microRNAs (miRNAs) in regulating drug resistance and leukemic stem cell (LSC) fate, we performed global transcriptome profiling in treatment-naive chronic myeloid leukemia (CML) stem/progenitor cells and identified that miR-185 levels anticipate their response to ABL tyrosine kinase inhibitors (TKIs). miR-185 functions as a tumor suppressor: its restored expression impaired survival of drug-resistant cells, sensitized them to TKIs in vitro, and markedly eliminated long-term repopulating LSCs and infiltrating blast cells, conferring a survival advantage in preclinical xenotransplantation models. Integrative analysis with mRNA profiles uncovered PAK6 as a crucial target of miR-185, and pharmacological inhibition of PAK6 perturbed the RAS/MAPK pathway and mitochondrial activity, sensitizing therapy-resistant cells to TKIs. Thus, miR-185 presents as a potential predictive biomarker, and dual targeting of miR-185-mediated PAK6 activity and BCR-ABL1 may provide a valuable strategy for overcoming drug resistance in patients.

• Authors: Hanyang Lin, Katharina Rothe, Min Chen, Andrew Wu, Artem Babaian, Ryan Yen, Jonathan Zeng, Jens Ruschmann, Oleh I Petriv, Kieran O'Neill, Tobias Maetzig, David J H F Knapp, Naoto Nakamichi, Ryan Brinkman, Inanc Birol, Donna L Forrest, Carl Hansen, R Keith Humphries, Connie J Eaves, Xiaoyan Jiang
• Journal: Blood (Blood) Vol. 136 Issue 5 Pg. 596-609 (07 30 2020) ISSN: 1528-0020 [Electronic] United States
• PMID: 32270193 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2020 by The American Society of Hematology.

Chemical References

• MIRN185 microRNA, human
• MicroRNAs
• Protein Kinase Inhibitors
• PAK6 protein, human
• p21-Activated Kinases

Topics

• Animals
• Drug Resistance, Neoplasm (genetics)
• Gene Expression Regulation, Leukemic (genetics)
• Heterografts
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, genetics, metabolism)
• Mice
• Mice, SCID
• MicroRNAs (genetics, metabolism)
• Neoplastic Stem Cells (metabolism, pathology)
• Protein Kinase Inhibitors (therapeutic use)
• Signal Transduction (physiology)
• p21-Activated Kinases (genetics, metabolism)